Search PubMed⌕ Search

Biomedical subjects

K Ushijima

Publications and source records attributed to K Ushijima.

108 records · Page 6Linked to original sources
PubMed1977

Early carcinoma in the periampullary region: report of two cases.

Two cases of early carcinoma in the periampullary region detected microscopically are reported. In Case 1, the carcinoma was found in part of an adenomatous polyp resected transduodenally. In Case 2, carcinoma was located within 1 cm from the main pancreatic duct hidden in the surrounding inflammatory tissue of the pancreatic head excised by radical pancreatoduodenectomy. Case 1 survived more than 3 years after the operation and Case 2 more than 5 years without any evidence of recurrence. The practical significance of such early carcinoma is discussed.

Adenocarcinoma↗
PubMed1976

Characterization of two different factors chemotactic for cancer cells from tumor tissue.

Two different factors chemotactic for cancer cells were extracted in pseudoglobulin fraction of rat ascites hepatoma transplanted tissue. After chromatography on Sephadex G-50 and CM-sephadex, these factors were separated by gel filtration on Sephadex G-100. The factor a was further fractionated by immunoadsorbent chromatography with goat antirat gamma-globulin antibody and then with rabbit antirat hemoglobin antibody; it was a protein with a molecular weight of about 78,000, resembling a chemotactic factor previously reported, and its activity was thermolabile. The previously undescribed factor b was also a protein with a molecular weight of about 14,000 and its activity was thermostable. Intradermal injection of these factors at low concentrations induced an extravascular migration of circulating tumor cells and formation of metastatic secondary tumors; and little difference in the in vivo effect between these factors was observed. It was thus assumed that the combined action of these two factors may be involved in malignant invasion.

Animals↗
PubMedDate not supplied

Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer.

The molecular basis of T-cell-mediated recognition of ovarian cancer cells remains to be fully addressed. In this study we investigated HLA class I restriction and directed antigens of cytotoxic T lymphocytes (CTL) at the sites of ovarian cancer. Three HLA-class-I-restricted CTL lines were established from the tumor sites of ovarian cancer by culturing tumor-infiltrating lymphocytes or tumor-associated ascitic lymphocytes with interleukin-2: (1) HLA-A2402-restricted and ovarian-adenocarcinoma-specific CTL, (2) HLA-A2-restricted CTL recognizing histologically different cancers, and (3) HLA-B52-restricted and ovarian-cancer-specific CTL. HLA-A0201, HLA-A0206 and HLA-A0207 tumor cells were lysed by the HLA-A2-restricted CTL. HLA-B52 restriction of the third CTL line was confirmed by the transfection of HLA-B5201 cDNA into the tumor cells. The HLA-A2-restricted CTL recognized the SART-1, but not the MAGE-1 or MAGE-3 antigen. These results may facilitate a better understanding of the molecular basis of tumor-specific immunity at the tumor site of ovarian cancer.

Animals↗
PubMedDate not supplied

Failure of glutathione peroxidase to reduce transient ischemic injury in the rat hippocampal CA1 subfield.

It has been postulated that oxygen radical species are produced by ischemia-reperfusion in the brain and play a critical role in neuronal damage. Glutathione peroxidase (GSHPx), one of the antioxidative enzymes, detoxifies hydrogen peroxide, which is the source of a hydroxyl radical that reacts with polyunsaturated fatty acids of the cell membrane, resulting in cell death. The present study was undertaken to investigate the postischemic effect of exogenous GSHPx upon rats subjected to global forebrain ischemia and reperfusion. GSHPx or artificial cerebrospinal fluid (aCSF) as a vehicle for GSHPx was administered into the left cerebral ventricle 15 min after a 5-min 4-vessel occlusion. Neuronal damage and apoptosis were assessed 4 days after ischemic insult using cresyl violet stain and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method, respectively. Most pyramidal neurons in the hippocampal CA1 subfield were degenerated and their nuclei were stained by the TUNEL in both GSHPx- (80 and 200 units/kg) and aCSF-treated animals. Neurons in other subfields of the hippocampus and dentate gyrus survived. Our further attempt to improve the outcome with a higher dose of GSHPx was unsuccessful because all rats receiving 400 units/kg died soon after the intracerebroventricular injection due to respiratory insufficiency. We conclude that the postischemic treatment with GSHPx does not ameliorate the apoptotic neuronal death of hippocampal CA1 in this transient ischemia model under the conditions used here.

Animals↗
PubMedDate not supplied

Remission of metastatic cervical adenocarcinoma with weekly paclitaxel.

We report the use of paclitaxel in the successful treatment of a patient with recurrent adenocarcinoma of the cervix. Paclitaxel, 70 mg/m2 by 1-h infusion weekly, was administered to a 59-year-old patient with cervical adenocarcinoma showing lung metastasis. She showed partial clinical response after seven cycles, and at the completion of 20 cycles she showed complete response, which was confirmed by chest X-ray and computed tomography scan. Toxicities including neurotoxicity were mild. She showed an objective response to treatment for over 8 months, and she enjoyed a favorable quality of life during and after treatment. Weekly paclitaxel was very well tolerated, yet was effective for recurrent cervical adenocarcinoma.

Adenocarcinoma↗
PubMedDate not supplied

Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.

BACKGROUND: We aimed to evaluate the in vitro and in vivo effects of poly [L-lactic acid] microsphere containing cisplatin (CDDP-MS) for intraperitoneal (i.p.) chemotherapy for ovarian cancer. METHODS: We initially examined the in vitro and in vivo profile of cisplatin release from the CDDP-MS, then this drug delivery system was evaluated in 15 patients. RESULTS: The in vitro study showed that cisplatin was released constantly over a 3-week period. Rats in the CDDP-MS group had a significantly lower peak serum concentration of platinum compared with rats in the aqueous cisplatin solution (CDDP-S) group; the serum concentration of platinum showed a gradual decline. The ascitic fluid concentration of platinum also gradually decreased in the CDDP-MS group. We treated 15 patients with recurrent ovarian cancer with CDDP-MS containing 200 mg of cisplatin (n = 5) or CDDP-S containing 100 mg of cisplatin (n = 10) administered i.p. The peak serum and ascites concentrations of platinum were lower immediately after administration of CDDP-MS than after administration of CDDP-S, but increased over time in the CDDP-MS group, reflecting the slow-release effect of CDDP-MS. Grade 1 to 2 leukopenia and/or neutropenia occurred in 2 of 5 patients. No thrombocytopenia or renal or neurologic toxicity was observed; CONCLUSION: These findings indicate that the i.p. administration of CDDP-MS increased the dose intensity of cisplatin and appeared to be safe and effective for the treatment of ovarian cancer.

Adult↗